title: Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris.
abstract: OBJECTIVE
  The prostamides (prostaglandin-ethanolamides) and prostaglandin (PG) glyceryl esters are biosynthesized by COX-2 from the respective endocannabinoids anandamide and 2-arachidonyl glycerol. Agonist studies suggest that their pharmacologies are unique and unrelated to prostanoid receptors. This concept was further investigated using antagonists.
  
  
  METHODS
  The isolated feline iris was used as a key preparation, where prostanoid FP receptors and prostamide activity co-exist. Activity at human recombinant FP and other prostanoid receptors was determined using stable transfectants.
  
  
  RESULTS
  In the feline iris, AGN 204396 produced a rightward shift of the dose-response curves for prostamide F2alpha and the prostamide F2alpha analog bimatoprost but did not block the effects of PGF2alpha and synthetic FP receptor agonists. Studies on human recombinant prostanoid receptors confirmed that AGN 204396 did not behave as a prostanoid FP receptor antagonist. AGN 204396 exhibited no antagonism at DP and EP1-4, but was a highly effective TP receptor antagonist. Contrary to expectation, the FP receptor antagonist AL-8810 efficaciously contracted the cat iris. AGN 204396 did not affect AL-8810 induced contractions, demonstrating that AL-8810 and AGN 204396 are pharmacologically distinct. Unlike AL-8810, the ethylamide derivate of AL-8810 was not an agonist. Al-8810 did not block prostamide F2alpha activity. Finally, AGN 204396 did not block PGE2-glyceryl ester activity.
  
  
  CONCLUSIONS
  The ability of AGN 204396 to selectively block prostamide responses suggests the existence of prostamide sensitive receptors as entities distinct from receptors recognizing PGF2alpha and PGE2-glyceryl ester.
authors.affiliation: Department of Biological Sciences, Allergan, Inc., Irvine, CA 92612, USA. woodward_david@allergan.com
authors.forename: D F
authors.initials: DF
authors.lastname: Woodward
authors.forename: A H
authors.initials: AH
authors.lastname: Krauss
authors.forename: J W
authors.initials: JW
authors.lastname: Wang
authors.forename: C E
authors.initials: CE
authors.lastname: Protzman
authors.forename: A L
authors.initials: AL
authors.lastname: Nieves
authors.forename: Y
authors.initials: Y
authors.lastname: Liang
authors.forename: Y
authors.initials: Y
authors.lastname: Donde
authors.forename: R M
authors.initials: RM
authors.lastname: Burk
authors.forename: K
authors.initials: K
authors.lastname: Landsverk
authors.forename: C
authors.initials: C
authors.lastname: Struble
mesh_terms: D000818:Animals; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002415:Cats; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000502:physiology; D015232:Dinoprostone / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D066298:In Vitro Techniques; D007498:Iris / Q000187:drug effects*; D010080:Oxazoles / Q000494:pharmacology*; D011982:Receptors, Prostaglandin / Q000187:drug effects; D011994:Recombinant Proteins
chemical_list: C518976:AGN 204396; C518977:AL 8810 ethylamide; D019086:Bridged Bicyclo Compounds, Heterocyclic; D010080:Oxazoles; D011982:Receptors, Prostaglandin; D011994:Recombinant Proteins; C518978:prostaglandin E2 glyceryl ester; C121227:AL 8810; D015237:Dinoprost; D015232:Dinoprostone